|
[an error occurred while processing this directive]
|
Item #13
Reduction
of Fatty Acids Improves Insulin Secretion in Type 2 Diabetics
Acute
reduction of circulating fatty acids with Acipimox improves insulin
secretion in type 2 diabetic patients with low hemoglobin A1c levels.
Investigators from Norwegian University of Science and Technology, in
Trondheim, Norway, studied 21 patients with type 2 diabetes and
hypertriglyceridamia alongside 10 age-matched non-diabetic controls.
Subjects underwent two hyperglycemic clamps for 120 minutes each with
an infusion of Intralipid and heparin from minute 60 to 120. In one of
the tests, subjects received 250 mg of Acipimox 60 minutes before the
hyperglycemic clamp.
A third test including 17 of the diabetic patients was also conducted.
In this test, patients followed a three-day low-fat diet before
undergoing hyperglycemic clamps with Acipimox.
Results showed that Acipimox lowered fatty acid levels and increased
insulin sensitivity in both diabetic and non-diabetic subjects.
Half of the diabetic patients -- those with the lowest levels of
hemoglobin A1c -- showed increased insulin secretion during minutes 60
to 120 after taking Acipimox.
Neither the diabetic patients with higher hemoglobin A1c nor the
non-diabetic controls showed any change in insulin secretion rates
with Acipimox.
The low-fat diet reduced energy from fat from 39 to 23 percent, but
had no effect on fatty acid levels or insulin response during the
hyperglycemic clamp test.
Am J Physiol
Endocrinol Metab 2003; 284(1): E129-137
================================
FACT:
More
than 44 million Americans are now considered obese. The rising rates
of obesity correspond with an increase in the prevalence of diabetes.
[an error occurred while processing this directive]
|
[an error occurred while processing this directive]
|
